BGOG-en-10

Randomized, Multi-Center, Double Blind Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

Sponsor:  AstraZeneca

Participating sites:

• UZ Leuven, Leuven
• UZ Gent, Gent
• CHU UCL St-Luc, Bruxelles
• Hôpital de Libramont, Libramont
• AZ Groeninge, Kortrijk
• AZ Sint Jan Brugge, Brugge
• Grand Hôpital de Charleroi, Charleroi
• Clinique CHC Montlégia, Liège
• Jessa Ziekenhuis, Hasselt

Learn More ->

BGOG-en-9

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

• UZ Leuven, Leuven
• CHU UCL St-Luc, Bruxelles
• UZ Antwerpen, Antwerpen
• AZ Maria Middelares, Gent
• AZ Delta, Roeselare

Learn More ->

BGOG-en-6

A Phase 3, Randomized, Double-blind, Multicenter Study Comparing TSR-042 plus Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin plus Placebo in Patients with Recurrent or Advanced Endometrial Cancer Who Had Received no Previous Systemic Anticancer therapy for Advanced or Metastatic Disease

Sponsor: GSK/Tesaro

Participating sites:

• UZ Leuven, Leuven
• CHU de Liège, site Sart Tilman, Liège
• OLV Aalst, Aalst

Learn More ->

BGOG-ov-55

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Sponsor: ImmunoGen

Participating sites:

• Hôpital de Libramont, Libramont
• UZ Leuven, Leuven
• OLV Aalst, Aalst
• UZ Antwerpen, Antwerpen
• AZ Sint Lucas, Gent
• AZ Klina, Roeselare

Learn More ->

BGOG-cx-9

An Open-Label, Randomized, Phase 3 Clinical Trial of the checkpoint inhibitor REGN2810 versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or metastatic Platinum-Refractory Cervical Carcinoma

Sponsor: Regeneron Pharmaceuticals, Inc

Participating sites:

• CHU UCL Namur, site Sainte Elisabeth, Namur
• UZ Leuven, Leuven
• Clinique CHC Montlégia, Liège
• Institut Jules Bordet, Bruxelles
• CHU UCL St. Luc, Bruxelles
• OLV Aalst, Aalst
• CHU de Liège, site Sart Tilman, Liège

Learn More ->

BGOG-cx-8

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® ®-TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer

Sponsor: Genmab

Participating sites:

• UZ Leuven, Leuven
• CHU de Liège, site Sart Tilman, Liège
• UZ Antwerpen, Antwerpen
• CHU UCL St-Luc, Bruxelles
• Grand Hôpital de Charleroi, Charleroi
• CHU UCL St-Luc, Bruxelles
• AZ Sint-Jan Brugge, Brugge
• UZ Gent, Gent
• Hôpital de Libramont, Libramont

Learn More ->

BGOG-ov-46

Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients

Sponsor: AstraZeneca

Participating sites:

• AZ Nikolaas, St-Niklaas
• AZ Damiaan, Oostende
• OLV Aalst, Aalst
• UZ Leuven, Leuven
• CHU UCL Namur, site Sainte Elisabeth, Namur

Learn More ->

BGOG-ov-44

A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Sponsor: GSK/Tesaro

Participating sites:

• UZ Leuven, Leuven
• AZ Sint-Jan Brugge, Brugge
• CHU St. Pierre, Bruxelles
• AZ Klina, Brasschaat

Learn More ->

BGOG-ov-43

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the FirstLine Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

• AZ Maria Middelares, Gent
• Imelda Ziekenhuis, Bonheiden
• Grand Hôpital de Charleroi, Charleroi
• Hôpital de Libramont, Libramont
• UZ Leuven, Leuven
• UZ Gent, Gent
• Jessa Ziekenhuis, Hasselt
• CHU de Liège, site Sart Tilman, Liège
• UZ Antwerpen, Antwerpen
• CHU UCL St-Luc, Bruxelles

Learn More ->

BGOG-cx-6

A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Learn More ->

BGOG-cx-2B

A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer.

Learn More ->

BGOG-cx3

Prospective randomized Phase II trial comparing doxorubicin alone versus atezolizumab alone versus doxorubicin and atezolizumab in recurrent cervical cancer.

Learn More ->

BGOG-ov-39

A phase III, multicenter, randomized, study of Atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.

Learn More ->

BGOG-ov-29

A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.

Learn More ->

BGOG-ov-38

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy.

Learn More ->

BGOG-ov-26

Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Niraparib Versus Placebo in women who have not progressed after first line chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Learn More ->

BGOG-ov-19

Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.

Learn More ->

BGOG-ov-18

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.

Learn More ->

BGOG-ov-16

A non-interventional Belgian study to collect data on the safety and efficacy of frontline Bevacizumab treatment in ovarian cancer patients ≥70 years.

Learn More ->

BGOG-cx-2

A Randomized Phase III Trial comparing radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer.

Learn More ->

BGOG-v-1

Groningen International Study on Sentinel Lymph Nodes in Vulvar Cancer II – An observational study

Learn More ->

BGOG-cx-1

Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5 or 6) + paclitaxel 175 mg/m2  with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma.

Learn More ->

BGOG-ov-15

A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy

Learn More ->

BGOG-ov-14

A Phase 3 Randomized Double-blind Trial of Maintenance with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer.

Learn More ->

BGOG-ov-11

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum.

Learn More ->

BGOG-ov-9

A Randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer.

Learn More ->

BGOG-ov-8

Phase III, multicenter, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.

Learn More ->

BGOG-ov-6

A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.

Learn More ->

BGOG-ov-5

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers.

Learn More ->

BGOG-ov-4

Phase III Randomised Study of Bevacizumab plus Chemotherapy versus Chemotherapy alone in Patients with Platinum Resistant Ovariumcancer.

Learn More ->

BGOG-ov-2

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Learn More ->

BGOG-ov-1

A Phase II international multicenter randomized study testing the effect on survival of prolonging platinum-free interval in patients with ovarian cancer recurring between 6 and 12 months after previous platinum based chemotherapy.

Learn More ->